However, a systemic review of the safety and efficacy of anti-IL-1 targeted therapies, including Anakinra, Canakinumab, Gevokizumab, and Rilonacept, showed no positive treatment effects on preserving pancreatic islet function and endogenous insulin production in patients with T1D (162–164), as reviewed in (165), highlighting the need for further research to clarify their therapeutic potential in T1D or T2D (119). This evidence concerns the gene INS and type 1 diabetes mellitus.